Last reviewed · How we verify

NTC srl — Portfolio Competitive Intelligence Brief

NTC srl pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Levofloxacin + dexamethasone followed by dexamethasone Levofloxacin + dexamethasone followed by dexamethasone phase 3 Fluoroquinolone antibiotic + corticosteroid combination Bacterial DNA gyrase, topoisomerase IV (levofloxacin); glucocorticoid receptor (dexamethasone) Infectious Disease / Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Farmoquimica S.A. · 1 shared drug class
  2. Federal University of São Paulo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NTC srl:

Cite this brief

Drug Landscape (2026). NTC srl — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ntc-srl. Accessed 2026-05-14.

Related